NCAM1 and cancer: Cell counts of CD3+ T, CD3+CD4+ Th, CD3+CD8+ CTL, CD16+CD56+ NK, CD19+ B and the percentage of PD-1 positive cells decreased in cancer patients, supported impaired innate and adaptive immunity and lower T cell activation.